| pubmed-article:1980339 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1980339 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1980339 | lifeskim:mentions | umls-concept:C0022688 | lld:lifeskim |
| pubmed-article:1980339 | lifeskim:mentions | umls-concept:C1536403 | lld:lifeskim |
| pubmed-article:1980339 | lifeskim:mentions | umls-concept:C0079785 | lld:lifeskim |
| pubmed-article:1980339 | lifeskim:mentions | umls-concept:C1880177 | lld:lifeskim |
| pubmed-article:1980339 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:1980339 | pubmed:dateCreated | 1991-2-26 | lld:pubmed |
| pubmed-article:1980339 | pubmed:abstractText | The complement receptor CR3 molecule functions in direct intercellular contacts mediated by its beta chain, CD18. Similarly to the Fc receptor (CD16), CR3 is a marker of human natural killer cells. We have shown that opsonization of NK targets with iC3b leads to their increased lytic sensitivity. Opsonization could be achieved by incubating certain B and T cell lines in human serum. The expression of CR2 was a prerequisite for C3 fragment fixation. The CR2 negative cell line, P3HR1 could be opsonized by incubation in human serum when induced to express the EBV envelope glycoprotein gp350. C3b or iC3b could also be deposited artificially on cell surfaces by chemical coupling to surface reactive antibodies. Similarly to the function of macrophages and monocytes, contact with opsonized targets exclusively through the iC3b binding site of CR3 did not seem to trigger NK function. We attempted to clarify the functional role of other CR3 ligands. The beta chain of the molecule, CD18, was essential to the NK effect. The NK targets did not seem to interact with the beta-glucan binding epitope on the alpha chain of CR3, CD11b. On the other hand, the cytolytic function could be enhanced through this epitope with the appropriate ligand. | lld:pubmed |
| pubmed-article:1980339 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1980339 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1980339 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1980339 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1980339 | pubmed:issn | 0161-5890 | lld:pubmed |
| pubmed-article:1980339 | pubmed:author | pubmed-author:KleinEE | lld:pubmed |
| pubmed-article:1980339 | pubmed:author | pubmed-author:YefenofEE | lld:pubmed |
| pubmed-article:1980339 | pubmed:author | pubmed-author:Di RenzoLL | lld:pubmed |
| pubmed-article:1980339 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1980339 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:1980339 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1980339 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1980339 | pubmed:pagination | 1343-7 | lld:pubmed |
| pubmed-article:1980339 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:meshHeading | pubmed-meshheading:1980339-... | lld:pubmed |
| pubmed-article:1980339 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1980339 | pubmed:articleTitle | Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. | lld:pubmed |
| pubmed-article:1980339 | pubmed:affiliation | Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:1980339 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1980339 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1980339 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1980339 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1980339 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1980339 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1980339 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1980339 | lld:pubmed |
